SEC Form SC 13G/A filed by Eledon Pharmaceuticals Inc. (Amendment)

2/9/22 9:11:44 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ELDN alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 1 ELEDON PHARMACEUTICALS INC COMMON STOCK Cusip #28617K101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #28617K101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 504,371 Item 8: 0 Item 9: 504,371 Item 11: 3.525% Item 12: HC Cusip #28617K101 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 504,371 Item 8: 0 Item 9: 504,371 Item 11: 3.525% Item 12: IN Item 1(a). Name of Issuer: ELEDON PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 19900 MACARTHUR BLVD., SUITE 500 IRVINE, CA 92612 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 28617K101 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 504,371 (b) Percent of Class: 3.525% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 504,371 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ELEDON PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of ELEDON PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2022 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2022, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ELEDON PHARMACEUTICALS INC at December 31, 2021. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $ELDN alert in real time by email

Date

Price Target

Rating

Analyst

5/13/2022

$25.00 → $15.00

Overweight

Cantor Fitzgerald

11/24/2021

$35.00 → $25.00

Buy

HC Wainwright & Co.

SEC Form SC 13G/A filed by Eledon Pharmaceuticals Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $ELDN

$ELDN Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Eledon Pharma, Maintains $16 Price Target

Eledon Pharmaceuticals Presents Updated Data On Tegoprubart For Preventing Organ Rejection In Kidney Transplant Patients At American Transplant Congress

12 Health Care Stocks Moving In Friday's After-Market Session

$ELDN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)

$ELDN SEC Filings

$ELDN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$ELDN Large Ownership Changes

This live feed shows all institutional transactions in real time.

$ELDN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$ELDN Press Releases

Fastest customizable press release news feed in the world

SEC Form 424B5 filed by Eledon Pharmaceuticals Inc.

SEC Form 424B5 filed by Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 4 filed by Large owner Bvf Partners L P/Il

SEC Form 4 filed by President Perrin Steven

SEC Form 4 filed by Chief Executive Officer Gros David-Alexandre C

SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Eledon Pharmaceuticals Inc.

Cantor Fitzgerald resumed coverage on Eledon Pharmaceuticals with a new price target

HC Wainwright & Co. reiterated coverage on Eledon Pharmaceuticals with a new price target

SVB Leerink reiterated coverage on Eledon Pharmaceuticals with a new price target

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

$ELDN Financials

Live finance-specific insights

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results

Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

$ELDN Leadership Updates

Live Leadership Updates

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Recent Analyst Ratings for
$ELDN

$ELDN
Market Insights

$ELDN
Insider Purchases

$ELDN
SEC Filings

$ELDN
Insider Trading

$ELDN
Large Ownership Changes

$ELDN
Analyst Ratings

$ELDN
Press Releases

$ELDN
Financials

$ELDN
Leadership Updates